Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 57 clinical trials
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (CHANGEABLE)

, NBN, PTEN, RAD50, RAD51C, RAD51D, WRN) pathogenic/suspected pathogenic germline mutation, so as to explore the possibility of more combined therapy for breast cancer to achieve better therapeutic

  • 09 Jul, 2022
  • 1 location
Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

>To explore molecular correlates of the relationship between mutations in Akt/ PIK3CA/PTEN pathway and response to AZD5363 +Olaparib+ Durvalumab To understand the role of tumour

  • 22 Jan, 2021
  • 1 location
Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma

RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with recurrent or progressive low-grade glioma.

  • 07 Nov, 2020
  • 1 location
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

The combination treatment of protein kinase B (AKT) inhibitor, afuresertib, with androgen synthesis enzyme inhibitor, LAE001, may provide an effective treatment for metastatic castration resistant prostate cancer (m-CRPC) patients who have progressed/drug resistant following prior standard care treatments of any anti-androgen. This study intends to identify the most appropriate combined …

bone scan
hormone therapy
other therapies
  • 10 Aug, 2022
  • 17 locations
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II)

Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression. Afuresertib plus chemotherapy has demonstrated anti-tumor efficacy and an acceptable safety profile in patients with PROC in a published Phase I/II …

  • 10 Aug, 2022
  • 47 locations
Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer (ADDItion)

This multicenter Phase I/II trial consists of two stages: a phase I stage in patients with castration resistant prostate cancer in which the recommended phase II dose will be determined for ipatasertib administered in combination with darolutamide; and a phase II neoadjuvant stage in which patients with high risk prostate …

  • 21 Jul, 2022
  • 3 locations
TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

(excluding primary brain tumors) harboring germline PTEN inactivating mutations.

  • 01 May, 2022
  • 7 locations
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281)

/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the combination of

  • 26 Jul, 2022
  • 236 locations
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3)

) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss (Study Part B1) or PTEN loss without PIK3CA mutation (Study Part B2)

measurable disease
breast cancer
  • 08 Aug, 2022
  • 188 locations
Pre Operative Trastuzumab in Operable Breast Cancer

each arm). The levels of circulating chromatin will also be estimated at the same time points as CTC for these 40 patients. Evaluation of the paraffin blocks for pTEN loss6-8 and p95ErbB2

hormone therapy
adjuvant chemotherapy
tumor cells
platelet count
  • 14 May, 2022
  • 1 location